Welcome to our dedicated page for Vaxart news (Ticker: VXRT), a resource for investors and traders seeking the latest updates and insights on Vaxart stock.
Vaxart, Inc. (OTCQX: VXRT) is a clinical-stage biotechnology company developing oral recombinant vaccines delivered as pills, and its news flow reflects progress across multiple vaccine programs and corporate developments. The company regularly issues updates on its clinical trials for oral pill vaccine candidates targeting coronavirus, norovirus and influenza, as well as a therapeutic HPV vaccine candidate that it identifies as its first immune-oncology program.
Readers following Vaxart news can expect detailed reports on clinical data from its oral vaccine platform. For example, the company has announced Phase 1 results for a bivalent norovirus pill vaccine in lactating women, describing safety, tolerability and increases in norovirus-specific IgA in serum and breast milk, along with evidence of norovirus-specific IgA in infant stool. Vaxart has also highlighted data from second-generation norovirus constructs showing stronger blocking antibody responses and robust fecal IgA increases, and has presented these findings at scientific conferences such as the International Calicivirus Conference, World Vaccine Congress and IDWeek.
Vaxart’s news also covers its COVID-19 oral pill vaccine program, including enrollment and follow-up in a large Phase 2b trial funded under a Project NextGen/BARDA contract, and regulatory and funding updates such as a stop work order that delimited certain activities while maintaining support for follow-up of enrolled participants. In addition, the company has reported on an exclusive, worldwide license and collaboration agreement with Dynavax Technologies Corporation for its oral COVID-19 vaccine candidate, outlining the structure of upfront payments, an equity investment, and potential milestones and royalties.
Beyond clinical and partnership news, Vaxart issues releases on corporate actions, including stock listing changes, governance matters and capital markets events such as conference presentations and investor calls. Investors and observers can use this news feed to track the evolution of Vaxart’s oral vaccine platform, key trial readouts, collaboration milestones and changes in its trading venue and cost management initiatives.
Vaxart (NASDAQ: VXRT) has announced a strategic shift prioritizing its bivalent norovirus vaccine candidate following encouraging clinical trial results. The company has completed six trials demonstrating robust immunogenicity and safety in young adults and the elderly. Vaxart plans to report topline data from ongoing Phase 2 studies in mid-2023 and Q3 2023, respectively. The company ended 2022 with $95.7 million in cash but reported a net loss of $107.8 million, up from $70.5 million in 2021. Vaxart's research and development expenses surged to $81.1 million due to increased headcount and clinical trial costs, while revenue fell to $0.1 million from $0.9 million in 2021.
Vaxart, Inc. (NASDAQ: VXRT) will provide a business update and financial results for the year ending December 31, 2022, on March 15, 2023, after market close. A conference call with senior management is scheduled for the same day at 4:30 p.m. ET. Vaxart focuses on developing oral recombinant vaccines through a unique delivery system aimed at eliminating needle-stick injuries. Their product pipeline includes vaccines for coronavirus, norovirus, seasonal influenza, RSV, and HPV, along with existing intellectual property protections.
Vaxart, Inc. (NASDAQ: VXRT) announced the dosing of the first subject in its Phase 2 clinical trial for an oral bivalent norovirus vaccine on February 14, 2023. This trial aims to establish optimal vaccine dosing ahead of a possible Phase 3 trial. The vaccine demonstrated robust immunogenicity in Phase 1b, with IgA responses of 78% and 93% for GI.1 and GII.4 strains, respectively. Approximately 135 healthy adults will participate, analyzing safety and immunogenicity. The global norovirus market is estimated at over $10 billion, with significant annual health impacts in the U.S. Vaxart expects to report topline data in mid-2023.
Vaxart, Inc. (NASDAQ: VXRT) has appointed Phillip Lee as its new Chief Financial Officer, effective immediately. Lee brings nearly 15 years of experience in corporate finance, M&A, and advisory roles, having facilitated over $20 billion in transactions and raised over $1 billion in capital. CEO Andrei Floroiu expressed excitement about Lee's contribution to Vaxart's mission of combating infectious diseases through its oral vaccine platform. Vaxart focuses on developing innovative oral vaccines for various diseases, including COVID-19 and HPV, leveraging its proprietary delivery technology.
Vaxart, Inc. (Nasdaq: VXRT) announced a new study funded by the Bill & Melinda Gates Foundation to assess an oral norovirus vaccine aimed at protecting breastfeeding mothers and their infants. The study will investigate whether the vaccine induces antibodies in breast milk and transfers them to infants. Norovirus sickens approximately 21 million people in the U.S. annually, posing significant health risks, especially to children under five. The research aligns with Vaxart’s commitment to global access for low- and middle-income countries if the vaccine is effective.
Vaxart, Inc. (Nasdaq: VXRT) announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, will present at the World Vaccine & Immunotherapy Congress West Coast 2022 in San Diego on November 29, 2022. The presentation will focus on Vaxart’s Phase II trial results for its oral pill COVID-19 vaccine candidate, which recently showed positive top-line results. Vaxart specializes in developing oral recombinant vaccines and aims to create vaccines for various diseases, including COVID-19 and HPV.
Vaxart reported positive developments in its oral vaccine platform during the third quarter of 2022, including encouraging Phase II results for its COVID-19 candidate, demonstrating both serum and mucosal immunity.
The company ended the quarter with $114.8 million in cash but posted a net loss of $29.3 million, up from $17.6 million year-over-year, primarily due to increased R&D costs. With promising data in norovirus trials and key milestones expected in 2023, Vaxart aims to address significant market opportunities.
Vaxart, Inc. (NASDAQ: VXRT) will report its third-quarter financial results on November 8, 2022, after market close. A conference call will follow at 4:30 p.m. ET, where senior management will discuss the company's updates. Vaxart is focused on developing oral recombinant vaccines that can be delivered via tablets, aiming to provide alternatives for various viral infections, including COVID-19, norovirus, seasonal influenza, and RSV. Their innovative delivery platform reduces risks associated with traditional vaccinations, and the company has pending patent applications for its technology.
Vaxart, Inc. (Nasdaq: VXRT) announced that Dr. Sean Tucker and Dr. James Cummings will present at the World Vaccine Congress Europe 2022 in Barcelona on October 13. Dr. Tucker will discuss nasal mucosal responses to a SARS-CoV-2 oral tablet vaccine at 11:30 a.m. CET, while Dr. Cummings will present findings on immune responses to norovirus G1.1 in elderly subjects at 12:00 p.m. CET. Vaxart develops oral recombinant vaccines aimed at various viruses, emphasizing delivery without refrigeration and eliminating needle-stick risks.
Vaxart, Inc. (Nasdaq: VXRT) has announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The presentation will feature key executives including CEO Andrei Floroiu, CSO Dr. Sean Tucker, and CMO Dr. James Cummings, and will be available for viewing on the Company’s Events page starting September 12 at 7:00 a.m. ET. Vaxart specializes in developing oral recombinant vaccines, aiming to create accessible, needle-free vaccination options for various diseases.